ANITA FAZZIO: Open Payments
NPI 1215651476 · RACELAND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$590 in 20 payments from 12 companies in 2025. Trend: 2023 $229 · 2024 $478 · 2025 $590
Food & beverage: $590
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $148 |
| ABBVIE INC. | 3 | $101 |
| Neurocrine BioSciences, Inc. | 1 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $58 |
| UCB, Inc. | 1 | $32 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $25 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Eisai Inc. | 1 | $19 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, FANAPT, REXULTI, Fintepla, Auvelity, Korlym.
Industry payments across LA — which companies pay providers there.
